Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Anidulafungin

FDA-approved product (powder, intravenous), marketed as Eraxis.

Registered studies
43
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Anidulafungin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidemia
  • Candidiasis
  • Peritonitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
FDA pharmacologic class
Echinocandin Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX06; FDA class Echinocandin Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

43registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Anidulafungin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Anidulafungin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Of The Efficacy And Safety Of Anidulafungin Vs. Fluconazole In The Treatment Of Patients With Candidemia And/Or Other Forms Of Invasive Candidiasis

    NCT01176058 · start 2010-12

    Registered record
    Registry ID
    NCT01176058
    Conditions
    Candidemia
    Interventions
    Anidulafungin/Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2011-11
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionAnidulafungin/Fluconazole
    PhasePhase 3
    Registry statusTerminated

  • Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease

    NCT01249820 · start 2010-11

    Registered record
    Registry ID
    NCT01249820
    Conditions
    Leukemia; Myelodysplastic Syndrome; Leukemia, Myeloid, Acute
    Interventions
    anidulafungin 200 mg q48h; anidulafungin 300 mg q72h
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-11
    Completion
    2013-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Myelodysplastic Syndrome; Leukemia, Myeloid, Acute
    Interventionanidulafungin 200 mg q48h; anidulafungin 300 mg q72h
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU)

    NCT01047267 · start 2010-06

    Registered record
    Registry ID
    NCT01047267
    Conditions
    Invasive Candidiasis; Critically Ill
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-06
    Completion
    2011-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis; Critically Ill
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment

    NCT00934934 · start 2010-04

    Registered record
    Registry ID
    NCT00934934
    Conditions
    Ventilator Associated Pneumonia; Respiratory Tract Infection
    Interventions
    Normal Saline; anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-04
    Completion
    2012-08
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia; Respiratory Tract Infection
    InterventionNormal Saline; anidulafungin
    PhasePhase 2
    Registry statusTerminated

  • Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

    NCT00841971 · start 2010-02

    Registered record
    Registry ID
    NCT00841971
    Conditions
    Mycoses; Fungemia; Central Nervous System Fungal Infections; Lung Diseases, Fungal
    Interventions
    Anidulafungin; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2014-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses; Fungemia; Central Nervous System Fungal Infections; Lung Diseases, Fungal
    InterventionAnidulafungin; Fluconazole
    PhasePhase 4
    Registry statusCompleted

  • Anidulafungin in Patients With Hematologic Malignancies

    NCT01053884 · start 2009-10

    Registered record
    Registry ID
    NCT01053884
    Conditions
    Hematologic Malignancies
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-10
    Completion
    2011-09
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Malignancies
    InterventionAnidulafungin
    PhasePhase 2
    Registry statusTerminated

  • An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

    NCT00806351 · start 2009-08

    Registered record
    Registry ID
    NCT00806351
    Conditions
    Fungemia; Neutropenia; Candidiasis
    Interventions
    Active Anidulafungin; Active Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-08
    Completion
    2011-10
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungemia; Neutropenia; Candidiasis
    InterventionActive Anidulafungin; Active Caspofungin
    PhasePhase 3
    Registry statusTerminated

  • An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

    NCT00805740 · start 2009-04

    Registered record
    Registry ID
    NCT00805740
    Conditions
    Candidiasis; Fungemia
    Interventions
    Active anidulafungin; Active Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-04
    Completion
    2012-06
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis; Fungemia
    InterventionActive anidulafungin; Active Caspofungin
    PhasePhase 3
    Registry statusTerminated

  • Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)

    NCT00892359 · start 2009-04

    Registered record
    Registry ID
    NCT00892359
    Conditions
    Acute Renal Failure; Infection
    Interventions
    Anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-04
    Completion
    Not recorded
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Renal Failure; Infection
    InterventionAnidulafungin
    PhasePhase 2
    Registry statusUnknown

  • Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

    NCT00761267 · start 2009-02

    Registered record
    Registry ID
    NCT00761267
    Conditions
    Candidemia
    Interventions
    Anidulafungin; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-02
    Completion
    2018-02
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionAnidulafungin; Fluconazole
    PhasePhase 3
    Registry statusCompleted

  • A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

    NCT00940017 · start 2008-09

    Registered record
    Registry ID
    NCT00940017
    Conditions
    Aspergillosis; Candidemia
    Interventions
    anidulafungin and voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2008-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis; Candidemia
    Interventionanidulafungin and voriconazole
    PhasePhase 4
    Registry statusCompleted

  • Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins

    NCT01213823 · start 2008-09

    Registered record
    Registry ID
    NCT01213823
    Conditions
    Invasive Candidiasis; Candidemia
    Interventions
    Does not apply; Does not apply
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2008-09
    Completion
    2011-05
    Enrolment
    536

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis; Candidemia
    InterventionDoes not apply; Does not apply
    PhaseNot recorded
    Registry statusTerminated

  • Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene)

    NCT00620074 · start 2008-08

    Registered record
    Registry ID
    NCT00620074
    Conditions
    Aspergillosis
    Interventions
    voriconazole; anidulafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2009-02
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    Interventionvoriconazole; anidulafungin
    PhasePhase 4
    Registry statusTerminated

  • Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

    NCT00531479 · start 2008-07

    Registered record
    Registry ID
    NCT00531479
    Conditions
    Aspergillosis
    Interventions
    voriconazole; anidulafungin; voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2011-05
    Enrolment
    459

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspergillosis
    Interventionvoriconazole; anidulafungin; voriconazole
    PhasePhase 3
    Registry statusCompleted

  • Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

    NCT00689338 · start 2008-07

    Registered record
    Registry ID
    NCT00689338
    Conditions
    Invasive Candidiasis
    Interventions
    Anidulafungin; Fluconazole; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-05
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis
    InterventionAnidulafungin; Fluconazole; Voriconazole
    PhasePhase 3
    Registry statusCompleted